Synopsis

Source of validity: Scientific
Rating (out of 5): 2

There is emerging scientific evidence suggesting that Lactobacillus brevis may have a role in supporting or alleviating food allergies, but the strength of the evidence is limited and largely based on preclinical studies and a few small human trials. L. brevis is a species of lactic acid bacteria found in fermented foods and the human gut microbiome. Its potential benefits in food allergy are primarily linked to its ability to modulate the immune system, particularly by influencing the balance of Th1/Th2 immune responses and enhancing regulatory T cell activity, which helps in reducing allergic inflammation. Animal studies have demonstrated that administration of L. brevis can suppress IgE-mediated allergic reactions and mitigate symptoms in models of food allergy, such as ovalbumin-induced responses in mice. Additionally, some in vitro studies have shown that L. brevis can enhance gut barrier function and reduce intestinal inflammation, both of which are relevant for food allergy management.

However, clinical evidence in humans is sparse. A few small-scale clinical trials and case reports suggest that probiotics, including L. brevis (often as part of a multi-strain supplement), may reduce symptoms or improve tolerance in children with food allergies, but these studies often lack rigorous controls and their findings are not universally reproducible. Larger, well-controlled human trials are needed to confirm efficacy and determine optimal strains and dosages. Current guidelines do not yet recommend L. brevis specifically for food allergy treatment, but ongoing research continues to explore its potential.

More about lactobacillus brevis
More about Allergies (food)

Other ingredients used for Allergies (food)

Other health conditions supported by lactobacillus brevis

Products containing lactobacillus brevis

Douglas Laboratories Multi-Probiotic ® 40 Billion
Douglas Laboratories Multi-Probiotic ® 40 Billion